The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review (Q37854074)

24 August 2017

1 reference

title

The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review (English)

1 reference

24 August 2017

1 reference

Abdul Ahad

2

0 references

Sushama Talegaonkar

object named as

Sushama Talegaonkar

8

0 references

Mohd Aqil

object named as

Mohammed Aqil

5

0 references

Farhan J. Ahmad

object named as

Farhan Jalees Ahmad

7

0 references

author name string

Naseem Akhtar

1

1 reference

24 August 2017

Roop Kishan Khar

3

1 reference

24 August 2017

Manu Jaggi

4

1 reference

24 August 2017

Zeenat Iqbal

6

1 reference

24 August 2017

language of work or name

English

0 references

publication date

26 February 2011

1 reference

Expert Opinion on Therapeutic Patents

24 August 2017

1 reference

24 August 2017

21

1 reference

24 August 2017

4

1 reference

24 August 2017

561-576

1 reference

The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

A primer on the mechanics of P-glycoprotein the multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

How can we best use structural information on P-glycoprotein to design inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Availability and applications of ATP-binding cassette (ABC) transporter blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Cyclosporin A inhibits the extrusion pump function of p-glycoprotein in the inner ear of mice treated with vinblastine and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Mechanisms and strategies to overcome multiple drug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Does inhibition of P-glycoprotein lead to drug-drug interactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Multidrug resistance reversal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Structure-activity relationships of tariquidar analogs as multidrug resistance modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Pharmacological strategies for overcoming multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Natural and synthetic polymers as inhibitors of drug efflux pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Inhibition of P-glycoprotein function and expression by kaempferol and quercetin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Chemical penetration enhancers: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Effects of ketoconazole on digoxin absorption and disposition in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

Development and in vivo evaluation of an oral drug delivery system for paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.561784

10.1517/13543776.2011.561784

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference